Latest Commercialisation News

Epiminder Limited has achieved a major milestone with the first US implant of its Minder System at the University of Pennsylvania, kicking off a pivotal trial that could redefine epilepsy monitoring.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

Osteopore Limited has inked an exclusive collaboration with Majeton to commercialise its cutting-edge 3D-printed bioresorbable implants across China, Hong Kong, and Macau, unlocking significant growth potential in the region.

ION Video Ltd’s recent General Meeting saw overwhelming shareholder approval for crucial resolutions, including a securities consolidation and advisor options ratification.

Bass Oil reported steady December production with a notable gas sales agreement for the Vanessa field, signaling a strategic shift towards gas commercialization.

IperionX has received the last $4.6 million tranche of a $47.1 million U.S. Department of War award and 290 metric tons of titanium scrap, advancing its plan to scale titanium production in Virginia.

Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.

Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

4DMedical Limited has raised $150 million through a well-supported institutional placement to accelerate the commercialisation of its innovative lung imaging product CT – VQ™ in the US market. The capital raise comes with minimal dilution and increased insider confidence.

Vitrafy Life Sciences has secured a 12-month exclusive partnership with global animal reproduction leader IMV Technologies to co-develop and commercialise next-generation cryopreservation solutions for farm animals and aquaculture.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.